Medical News Today -
25 Sep 2013 11:00
Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) has announced the publication of a peer-reviewed paper demonstrating the success of its new DNA plasmid technology in generating therapeutic monoclonal antibodies. In this study in mice, a prototype monoclonal antibody construct encoding for an established anti-HIV monoclonal antibody (VRC01) was created as a DNA plasmid using Inovio's patented DNA optimization technologACy, including codon/RNA optimization and leader sequence utilization, and deliver...
Share this Article